These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 22454268)
1. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Patwa HS; Chaudhry V; Katzberg H; Rae-Grant AD; So YT Neurology; 2012 Mar; 78(13):1009-15. PubMed ID: 22454268 [TBL] [Abstract][Full Text] [Related]
2. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Donofrio PD; Berger A; Brannagan TH; Bromberg MB; Howard JF; Latov N; Quick A; Tandan R Muscle Nerve; 2009 Nov; 40(5):890-900. PubMed ID: 19768755 [TBL] [Abstract][Full Text] [Related]
3. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Bhidayasiri R; Fahn S; Weiner WJ; Gronseth GS; Sullivan KL; Zesiewicz TA; Neurology; 2013 Jul; 81(5):463-9. PubMed ID: 23897874 [TBL] [Abstract][Full Text] [Related]
4. Guidelines on the use of intravenous immune globulin for neurologic conditions. Feasby T; Banwell B; Benstead T; Bril V; Brouwers M; Freedman M; Hahn A; Hume H; Freedman J; Pi D; Wadsworth L Transfus Med Rev; 2007 Apr; 21(2 Suppl 1):S57-107. PubMed ID: 17397768 [TBL] [Abstract][Full Text] [Related]
5. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Tavee J; Brannagan TH; Lenihan MW; Muppidi S; Kellermeyer L; D Donofrio P; Muscle Nerve; 2023 Oct; 68(4):356-374. PubMed ID: 37432872 [TBL] [Abstract][Full Text] [Related]
6. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Dalakas MC Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245 [TBL] [Abstract][Full Text] [Related]
7. Evidence-based guideline: IV immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Li HF; Gao X; Hong Y; Patwa HS; Chaudhry V; Rae-Grant AD; So YT; Alto P Neurology; 2012 Sep; 79(13):1411; author reply 1411. PubMed ID: 23008223 [No Abstract] [Full Text] [Related]
8. Intravenous immunoglobulin in autoimmune neuromuscular diseases. Dalakas MC JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209 [TBL] [Abstract][Full Text] [Related]
10. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Cortese I; Chaudhry V; So YT; Cantor F; Cornblath DR; Rae-Grant A Neurology; 2011 Jan; 76(3):294-300. PubMed ID: 21242498 [TBL] [Abstract][Full Text] [Related]
11. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Soueidan SA; Dalakas MC Pediatr Res; 1993 Jan; 33(1 Suppl):S95-100. PubMed ID: 8433882 [TBL] [Abstract][Full Text] [Related]
12. Can we face the challenge of expanding use of intravenous immunoglobulin in neurology? Elovaara I; Hietaharju A Acta Neurol Scand; 2010 Nov; 122(5):309-15. PubMed ID: 20085560 [TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin therapy for neuromuscular disorders. Ross MA Semin Neurol; 2007 Sep; 27(4):340-6. PubMed ID: 17701871 [TBL] [Abstract][Full Text] [Related]
14. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B; Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075 [TBL] [Abstract][Full Text] [Related]
15. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. Illa I J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667 [TBL] [Abstract][Full Text] [Related]
16. [The use of intravenous immunglobulin in the treatment of autoimmune neuromuscular diseases]. Molnár MJ Ideggyogy Sz; 2006 Mar; 59(3-4):98-106. PubMed ID: 16634454 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Gürcan HM; Ahmed AR Ann Pharmacother; 2007 May; 41(5):812-23. PubMed ID: 17440006 [TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Dalakas MC Muscle Nerve; 1999 Nov; 22(11):1479-97. PubMed ID: 10514226 [TBL] [Abstract][Full Text] [Related]
19. Intravenous immunoglobulin in the treatment of neurologic disorders. Živković S Acta Neurol Scand; 2016 Feb; 133(2):84-96. PubMed ID: 25997034 [TBL] [Abstract][Full Text] [Related]
20. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Gloss D; Moxley RT; Ashwal S; Oskoui M Neurology; 2016 Feb; 86(5):465-72. PubMed ID: 26833937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]